Form 4: Design Therapeutics Director Acquires Stock Options

David Shapiro, a Director at Design Therapeutics, Inc., acquired 30,000 stock options.

Summary

• David Shapiro, a Director at Design Therapeutics, Inc., acquired 30,000 stock options on June 9, 2026.
• The stock options have an exercise price of $10.55 and an expiration date of June 8, 2036.
• These options are subject to vesting over 12 months following the grant date, with full vesting by the company's next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation and incentive mechanism for a director rather than a significant strategic or financial development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule over 12 months aligns the director's incentives with longer-term company performance.

Future Outlook

The stock options are set to vest over 12 months, with full vesting by the company's next annual meeting of stockholders, indicating a forward-looking incentive structure.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology and pharmaceutical sectors, often used to align executive and director incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as it aligns director interests with long-term company performance, potentially leading to increased shareholder value.
• Employees: This type of compensation for directors is standard and does not directly impact employees.

Next Steps

• Vesting of stock options over the next 12 months.
• Full vesting of options by the company's next annual meeting of stockholders.

Key Dates

Keywords

Design Therapeutics, DSGN, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing